Here is an interesting take (article attached below) on Ebola Vaccines by Seth Berkley, the CEO of Gavi, the Vaccine Alliance. He claims that successful clinical trail for Ebola vaccines is just the first step to bringing this outbreak under control; there are other hurdles that we also need to put our attention to.
First hurdle is paying for the vaccines if, or when they become available. Who is going to pay for the millions of doses required to end not just current epidemic, but also future ones? Second hurdle is the market: it costs a lot to bring vaccines to market and with a disease like Ebola that spreads sporadically, Berkley claims that "manufacturers would be unlikely to see a return on that investment". Other hurdles include the cost of scaling up these vaccines to commercial production, and also in their delivery to people who need it the most.
So, how do we address these challenges? The article provides two possible solutions. First is the "advanced purchase commitment, where donor funds are committed to guarantee manufacturers an agreed price once the vaccine has been developed."The second solution is the use of 'long-term flexible guaranteed funding', and the way it works is "by using long term government donor pledges to sell 'vaccine bonds' in capital markets, making large volumes of long-term funds available immediately for vaccine programs at the point in time when funds are required"
I am curious to hear thought from members about this article. Are there other challenges related to Ebola vaccines? What are you thoughts on the proposed solutions?
Link leads to: http://www.huffingtonpost.com/seth-berkley-md/ebola-vaccines-why-clinic_b_6263468.html